All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Clinical Trial Club | Optimal treatment sequencing in anemic MF
Bookmark this article
Video series
Clinical trial club 2024
On February 26, 2024, Scientific Education Support hosted a Clinical Trial Club entitled “Treatment sequencing for anemic myelofibrosis.” This live webinar was part of the MPN Hub Clinical Trial Club webinar series, “Novel agents for the treatment of anemic myelofibrosis.”
During the live webinar, myeloproliferative neoplasms expert, Angela Fleischman, discussed optimal treatment sequencing in anemic myelofibrosis. She began by outlining when to initiate therapy and first-line therapy considerations, before discussing treatment options for relapsed/refractory disease.
Fleischman then reviewed key data from recent and ongoing clinical trials, including a phase II trial investigating luspatercept and studies evaluating pacritinib, ruxolitinib, and momelotinib.
Video series
Clinical trial club 2024
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox